AptarGroup, Inc. (ATR)
| Market Cap | 8.90B +14.3% |
| Revenue (ttm) | 3.99B +9.0% |
| Net Income | 267.19M -36.3% |
| EPS | 4.14 -33.6% |
| Shares Out | 63.39M |
| PE Ratio | 33.93 |
| Forward PE | 23.12 |
| Dividend | $2.00 (1.43%) |
| Ex-Dividend Date | Nov 12, 2026 |
| Volume | 430,610 |
| Open | 141.23 |
| Previous Close | 143.17 |
| Day's Range | 140.12 - 143.20 |
| 52-Week Range | 110.95 - 148.63 |
| Beta | 0.32 |
| Analysts | Buy |
| Price Target | 163.88 (+16.78%) |
| Earnings Date | Oct 29, 2026 |
About ATR
AptarGroup, Inc. designs and manufactures drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, fragrance, facial skincare, color cosmetics, personal care, home care, and food and beverage markets. The company operates through three segments: Pharma, Beauty, and Closures. It provides dispensing pumps used to dispense sprays, liquids, or lotions from non-pressurized containers; fine-mist pumps for pharmaceutical and fragrance applications; and lotion pumps for viscous formulations,... [Read more]
Financial Performance
In 2025, AptarGroup's revenue was $3.78 billion, an increase of 5.42% compared to the previous year's $3.58 billion. Earnings were $392.79 million, an increase of 4.87%.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for ATR stock is "Buy." The 12-month stock price target is $163.88, which is an increase of 16.78% from the latest price.
News
AptarGroup management to meet with KeyBanc
Meeting to be held in Chicago on November 12 hosted by KeyBanc.
AptarGroup price target raised to $155 from $154 at BofA
BofA analyst George Staphos raised the firm’s price target on AptarGroup (ATR) to $155 from $154 and keeps a Buy rating on the shares. The firm updated the company’s model…
AptarGroup Earnings Call Transcript: Q3 2026
Q3 core sales grew 5% across all segments, while adjusted EPS was $1.52 and adjusted EBITDA margin was 21.3%. Emergency medicine destocking should be behind results after Q4; execution and North American Beauty profitability remain key priorities.
AptarGroup Earnings release: Q3 2026
AptarGroup released its Q3 2026 earnings on October 30, 2026, summarizing the period's financial results.
AptarGroup Slides: Q3 2026
AptarGroup has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 30, 2026.
AptarGroup Quarterly report: Q3 2026
AptarGroup has published its Q3 2026 quarterly earnings report on October 30, 2026.
AptarGroup reports Q3 adjusted EPS $1.52, consensus $1.47
Reports Q3 revenue $1.02B, consensus $980.76M. “We delivered broad-based revenue growth across all three segments. Pharma delivered impressive growth in central nervous system therapies, pulmonary, in...
AptarGroup reports Q3 adjusted EPS $1.52, consensus $1.47
Reports Q3 revenue $1.02B, consensus $980.76M. “We delivered broad-based revenue growth across all three segments. Pharma delivered impressive growth in central nervous system therapies, pulmonary, in...
AptarGroup sees Q4 EPS $1.39-$1.47, consensus $1.41
17:03 EDT AptarGroup (ATR) sees Q4 EPS $1.39-$1.47, consensus $1.41
AptarGroup raises quarterly dividend roughly 4% to 50c per share
AptarGroup (ATR) announced that its Board of Directors declared a quarterly cash dividend of 50c per share, an increase of approximately 4% from the previous quarterly dividend of $0.48 per…
Aptar Reports Third Quarter 2026 Results
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Reports Third Quarter 2026 Results.
Aptar Increases Quarterly Dividend to $0.50 Per Share
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Increases Quarterly Dividend to $0.50 Per Share.
Aptar Pharma enters collaboration with Stevanato Group
Aptar Pharma, part of AptarGroup (ATR) announced a collaboration with Stevanato Group (STVN) to provide system-level data supporting earlier evaluation of pre-filled syringe configurations for biotech...
AptarGroup initiated with a Neutral at UBS
UBS analyst Anojja Shah initiated coverage of AptarGroup (ATR) with a Neutral rating and $135 price target The company has a “robust moat” in its pharma segment, which represents 70%…
AptarGroup initiated with a Buy at Deutsche Bank
Deutsche Bank initiated coverage of AptarGroup (ATR) with a Buy rating and $150 price target The firm views the shares as “mispriced” given the company’s leading positions in nasal, ophthalmic…
AptarGroup price target lowered to $154 from $172 at BofA
BofA lowered the firm’s price target on AptarGroup (ATR) to $154 from $172 and keeps a Buy rating on the shares as the firm adjusted targets among its packaging and…
AptarGroup Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Leadership is focused on delivering 2026 commitments and long-term growth, with the Pharma segment as a key driver. Innovation, pipeline expansion, and a diversified revenue model support robust margins and growth, while a strong balance sheet enables continued investment and shareholder returns.
AptarGroup, Massachusetts General Hospital team on nose-to-brain drug delivery
AptarGroup (ATR) announced that it has signed an agreement for a research collaboration led by Alice Stanton from Massachusetts General Hospital, or MGH, to advance the science of nose-to-brain drug…
AptarGroup Transcript: Wells Fargo 21st Annual Healthcare Conference
Leadership is prioritizing customer centricity, innovation, and execution, with a focus on improving underperforming segments and leveraging early-stage partnerships in pharma. Beauty lags in North America, while pharma and injectables show strong growth. Major investments are complete, and IP protection remains a key focus.
AptarGroup price target lowered to $172 from $173 at BofA
BofA lowered the firm’s price target on AptarGroup (ATR) to $172 from $173 and keeps a Buy rating on the shares. The firm lowered its EPS forecasts for Q3, 2026…
AptarGroup Earnings Call Transcript: Q2 2026
Second quarter saw record sales and adjusted EPS above guidance, led by strong Pharma demand in injectables and consumer healthcare, while Beauty and Closures improved sequentially. Emergency medicine headwinds are expected to ease, supporting margin recovery and long-term growth targets.
AptarGroup Earnings release: Q2 2026
AptarGroup released its Q2 2026 earnings on July 31, 2026, summarizing the period's financial results.
AptarGroup Slides: Q2 2026
AptarGroup has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 31, 2026.
AptarGroup Quarterly report: Q2 2026
AptarGroup has published its Q2 2026 quarterly earnings report on July 31, 2026.
AptarGroup reports Q2 EPS $1.36, consensus $1.35
Reports Q2 revenue $1.03B, consensus $1.01B. “We were pleased to deliver revenue growth across all three segments during the quarter. Aptar Pharma continued to lead the way, driven by double-digit…